{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"COPERNICUS","nct_id":"NCT06667076","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=copernicus-nct06667076. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"COPERNICUS","arms":[{"description":"Participants will receive Amivantamab in combination with Lazertinib orally in 28-day cycles until disease progression, withdrawal of consent, death, or the investigator decides to discontinue treatment, whichever comes first.","label":"Cohort 1: Amivantamab and Lazertinib","type":"EXPERIMENTAL"},{"description":"Participants will receive Amivantamab in combination with chemotherapy (carboplatin and pemetrexed) intravenous (IV) infusion in 21-day cycles until disease progression, withdrawal of consent, death, or the investigator decides to discontinue treatment, whichever comes first.","label":"Cohort 2: Amivantamab and Chemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-12-26","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":480,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Amivantamab","type":"DRUG"},{"name":"Lazertinib","type":"DRUG"},{"name":"Chemotherapy: Pemetrexed","type":"DRUG"},{"name":"Chemotherapy: Carboplatin","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-05-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to 4 Years and 6 months"}],"references":[],"start_date":{"date":"2024-12-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT06667076"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/copernicus-nct06667076"}